Fig. 4: Eliglustat alters the immune cell composition and function of the tumour microenvironment.

a MC38-OVA tumour samples were collected from tumour-bearing mice on Day 21 with or without eliglustat and subjected to a CyTOF assay. The t-SNE plot shows all CD45⁺ cells, coloured according to the type of immunocyte (n = 3). b Proportions of CD4⁺ and CD8⁺ T cells in CD45⁺ T-cell clusters (n = 3). c,d Total TCRs, clonal type, unique TCRs (D50), and average CDR3 length of T cells from both the control and eliglustat-treated tumours and spleens were determined by using TCR-β CDR3 sequencing (n = 9). Box plots display the median (centre line) and minimum and maximum values (boxes) (b–d). Box colours (b–d): control (red), eliglustat treated (blue). e,f MC38 tumour-bearing mice 21 days after eliglustat treatment. CD8⁺ T cells were collected from dLNs and tumours, and the IFN-γ ELISPOT assay was performed with 4T1 or MC38 cell restimulation (n = 4). The data represent three independent experiments with similar results (b–f). Box plot whiskers extend to the minimum and maximum values, with the centre line indicating the median, and the box encompassing the interquartile range. P values were determined by unpaired two-sided t tests in (b, c, d and f). CON control, ELI eliglustst, dLN draining lymph node. Source data and exact p values are provided as a Source Data file.